SynAging announces extension of its collaboration with Europe's largest biopharmaceutical company Download PDF
First Commercial in vitro Test System for Human Neuroprotection in Proteopathic Diseases such as Alzheimer’s and Parkinson’s Download PDF
SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology Download PDF, 150 KB
Low Number Human Tau Oligomers (Proprietary Preparations)
Human 2N4R tau wild-type protein was produced in E. coli and purified to >95% purity. The monomer preparation is free from any neurotoxicity. Oligomers (human tau oligomers, hTO) and fibrils (hTF) are prepared using SynAging’s proprietary protocols.
Misfolded human-Tau-Oligomers (hTO), as seen above, are used at submicromolar concentrations (based on monomer) in vitro and in vivo to induce neurodegeneration and disease symptoms. The preparation largely consists of 170 kDa aggregates (trimers) and higher molecular weight species (> 300 kDa). The preparation is stable when stored frozen (-80°C). Every preparation is tested before use in client projects.
Further characterization was performed by size exclusion chromatography, negative stained electron microscopy, and circular dichroism.